Clinically, the reduction of CRP-induced IL-6 production with E2 pre-treatment shown by our result could indicate a key role of this hormone in the prevention or reduction of cytokine inflammatory response implicated in the development and maintenance of atherosclerosis. The gene discussed is CRP; the disease is atherosclerosis.